Literature DB >> 3155774

Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele.

T R Dykman, J A Hatch, M S Aqua, J P Atkinson.   

Abstract

The receptor for C3b/C4b (C3bR or CR1) has an unusual polymorphism in which three codominant alleles determine variants with a large difference in Mr (160,000, 190,000, or 220,000). We found an individual who has, in addition to the common 190,000 Mr molecule, a C3bR whose Mr is 250,000. In this proband and in some members of his family, this novel heterozygous phenotype can be isolated from 125I surface-labeled cells by iC3 or iC4 affinity chromatography or by immunoprecipitation with the use of polyclonal or monoclonal anti-C3bR. Relative to the 190,000 Mr C3bR, E from individuals in this family have 20 to 30% of the total receptor counts in the 250,000 Mr C3bR. However, on C3bR-bearing leukocytes there is a much larger amount of the 250,000 Mr C3bR (approximately 60%) relative to the 190,000 Mr C3bR. Similar to the other three C3bR variants, the Mr is 5,000 greater on polymorphonuclear cells than on E, and treatment of this new C3bR with endoglycosidase F decreases its Mr by approximately 10,000. Therefore, because this variant is inherited and has structural and functional similarities to the other three C3bR, we conclude that this 250,000 Mr CR1 probably represents a fourth allele.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Authors:  E V Ruggieri; P J Bugelski; J M Kaplan; D Everitt; J Lipani; D K Jorkasky; S C Boike; F DeClement; F D Moore; D J Herzyk
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

Review 2.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

Review 3.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

4.  Human mononuclear phagocyte molecules and the use of monoclonal antibodies in their detection.

Authors:  N Hogg
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

Review 5.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

6.  Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis.

Authors:  Swapan K Nath; John B Harley; Young Ho Lee
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

7.  Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism.

Authors:  V M Holers; D D Chaplin; J F Leykam; B A Gruner; V Kumar; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus.

Authors:  P Cornillet; P Gredy; J L Pennaforte; O Meyer; M D Kazatchkine; J H Cohen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

9.  Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Authors:  C-H Chen; I Ghiran; F J M Beurskens; G Weaver; J A Vincent; A Nicholson-Weller; L B Klickstein
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

10.  A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding.

Authors:  Daniel J Birmingham; Fawzi Irshaid; Katherine F Gavit; Haikady N Nagaraja; C Yung Yu; Brad H Rovin; Lee A Hebert
Journal:  Mol Immunol       Date:  2007-04-30       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.